Exploring the Sources for A Better Neurocare And Healthcare Through Neurology 2018

Exploring the Sources for A Better Neurocare And Healthcare Through Neurology 2018

(CME Accredited)

Pulsus Conferences hosts the 4th International Conference on Neurology and Healthcare(CME ACCREDITED) which outsources the new research standards in neuro care and advanced healthcare, providing the most integrated approach in academic and research part of healthcare studies. Neurology 2018 will be unique in the series of conferences which will provide interactive sessions regarding Neurocare and quality aspects followed in healthcare industries along with recent advances in the field of neurorobotics. It also provides an opportunity to showcase your research works and innovative works in front of the world for the global recognition.

The event is held in Berlin from September 17-18, 2018. 

CME Credits are Awarded for the Conference

Download Conference Brochure @ https://neurology.cmesociety.com/conference-brochure

Neurology 2018 will be a grand event which is focused on the theme “Broader Outlook in the Field of Neurology and Healthcare” and ensures better advancements in healthcare for the future. Neurology 2018 provides you with a great platform to interact with renowned speakers, neurologists and neurosurgeons and other healthcare professionals around the globe. Recent advancements in neurology, neurorobotics, neurosurgery, precision medicines are the trademark of this conference. Neurology 2018 will be a stepping stone to the future health care with its eminent speakers and organizing committee members.

Neurology 2018 serves as an emerging platform to discuss the recent advancements in neurology and healthcare which includes neurorobotics, deep brain stimulation, neurosurgery, precision medicine for neural disorders and more. Neurology 2018 will enlighten the public with the importance of neuro care and its advanced mode of treatments as well as the aspects of neuroscience. The conference also serves with trending works in the field of neurology and the recent research works by pioneer scholars. Recent advancements in neuroscience have shown the entry of technology into the field which had reduced the complexity of neurological examination, neurosurgery and other types of neuro treatments. The continuous research works in this field had introduced several vital information which is being used in this era of medicine. Thereby creating a world with the most advanced type of treatment and medicine which indeed provides a better healthcare for future. The future of neurorobotics has a widespread network which will, in turn, enhance the robotic market in a supportive way and hence showing a steep rise in the market.

In addition, attendees will enjoy special events and lecturers featuring specialists and top scholars. It is a perfect platform for neurology aspirants, practitioners and researchers to exchange & share their experiences, research findings of all aspects of neurology and healthcare.

Neurology 2018 will witness the gathering of the International blend of people from the neurological field, pharmaceutical, biotech & medical devices companies, business entrepreneurs, neurology consultants, R&D heads and decision makers from health care, contract research, clinical trials, leading universities and research institutions making it the largest endeavour from Pulsus Conferences.

If you would like to know more information about this conference,

Contact:

Chris Isaac

Program Director | Neurology 2018

Neurological Disorders | Huntington's Disease | Abstracts Invited | Neurology 2018 | CME | Pulsus Conferences

Huntington's Disease

Huntington's disease (HD) is a fatal condition typically characterized by involuntary movements and dementia. The disease is caused by genetically programmed degeneration of brain cells, called neurons, in certain areas of the brain. This causes uncontrolled movements, loss of intellectual faculties and emotional disturbance. The disease is a hereditary disorder passed on by a parent to child through a mutation in a gene.

In the United States, Huntington's disease occurs in about one of every 10,000 to 20,000 people. It affects males and females equally and crosses all ethnic and racial boundaries. Typically, symptoms begin between age 30 and 55.

Signs & Symptoms 

Early symptoms of Huntington's disease (HD) include mood swings, depression and irritability. Patients may notice problems in their daily activities such as driving, learning new things, remembering a fact or making a decision.

As the disease progresses, concentration and short-term memory decline and involuntary movements increase. The ability to walk, speak and swallow deteriorates. Eventually, patients become unable to care for themselves. Chocking, infection and heart failure are potentially fatal complications of the disease.

Diagnosis

To make a diagnosis of Huntington's disease (HD), a genetic test, using a blood sample, will be performed. This test is usually combined with a complete medical history and other neurological and laboratory tests. For individuals who are at risk of carrying the HD gene, testing can be performed before symptoms occur.

Information from brain scans such as computed tomography (CT),electroencephalography (EEG) and magnetic resonance imaging (MRI) may be part (magnetic resonance imaging) and may be reviewed as part of the diagnosis.

Treatment

Currently, there is no cure for Huntington's disease and no treatment to slow its progression. Treatments are available, however, to help control the symptoms.

Medications may help alleviate involuntary movements and may be used to help control hallucinations, delusions and violent outbursts. Anti-psychotic drugs can have severe side effects, though, including stiffness and sedation, and for that reason are used in the lowest possible doses. Anti-depressants are used for depression and tranquilizers can help with severe mood swings.

A special diet may be prescribed to help with swallowing problems and to prevent weight loss.

Studies are being conducted to determine if antioxidants and other agents help protect the brain and prevent degeneration in HD. So far, these studies have not shown any benefit.

Submit the abstracts 

neurocare2018@gmail.com

Courtesy : .ucsfhealth

Updates In Neurology | Stroke | Neurology 2018 | Abstracts Invited |

Thrombectomy beyond the conventional therapeutic window and in unwitnessed strokes

Abstract Submission at https://neurology.cmesociety.com/abstract-submission

Recently two trials reported results about the effectiveness of thrombectomy for patients with acute ischemic stroke with large-vessel occlusion of intracranial arteries who can be treated beyond the conventional 6 hours therapeutic window or who have unwitnessed strokes.

In the DAWN trial (DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo) patients were randomly assigned to thrombectomy plus standard care (the thrombectomy group) or to standard care alone (the control group) (Nogueira et al., 2018). The trial included patients with occlusion of a large cerebral vessel who presented between 6 and 24 hours after the onset of stroke; approximately 60% of the patients had had their first stroke symptoms when they woke up. To be included, “tissue window” criteria were required to detect evidence of ischemic but not yet infarcted brain tissue. Patients were included if evidence of a small infarct core on magnetic resonance imaging (MRI) or perfusion computed tomography (CT) in addition to evidence of a clinical deficit that was disproportionately severe relative to the infarct. The trial was halted on the basis of results of a prespecified interim analysis, which suggested a high probability of success. Results indicated that for every 2 patients who underwent thrombectomy, 1 additional patient had a better score for disability at 90 days (as compared with the results in the control group); for every 2.8 patients who underwent thrombectomy, 1 additional patient had functional independence at 90 days. The safety profile for thrombectomy did not differ significantly from the rates seen with standard medical care.

In the DEFUSE 3 (The Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke) trial patients were randomly assigned to thrombectomy plus standard care (the thrombectomy group) or to standard care alone (the control group) (Albers et al., 2018). The trial included patients with proximal middle-cerebral-artery or internal-carotid-artery occlusion, who could undergo initiation of endovascular therapy between 6 and 16 hours after the time that they had last been known to be well, including if they had awakened from sleep with symptoms of a stroke. Patients were eligible if they had an initial infarct size of less than 70 ml, and a ratio of the volume of ischemic tissue on perfusion imaging to infarct volume of 1.8 or more as estimated by CT perfusion or MRI diffusion and perfusion scans with the use of a dedicated software. Even this trial was halted on the basis of results of a prespecified interim analysis, which suggested a high probability of success. Results indicated that the thrombectomy group, as compared to the control group, had a favorable shift in the distribution of functional outcomes on the modified Rankin scale at 90 days (odds ratio, 2.77; P<0.001) and a higher percentage of patients who were functionally independent, defined as a score on the modified Rankin scale of 0 to 2 (45% vs. 17%, P<0.001). The 90-day mortality rate was 14% in the thrombectomy group and 26% in the control group (P = 0.05), and there was no significant between-group difference in the frequency of symptomatic intracranial hemorrhage (7% and 4%, respectively; P = 0.75) or of serious adverse events (43% and 53%, respectively; P = 0.18).

Taken together the results of those trials support that, in selected patients with acute ischemic stroke due to the occlusion of a large vessel, endovascular treatment may be associated with benefits even when performed beyond the 6-hour therapeutic window. Implementation of this treatment strategy requires advanced neuroimaging studies and expertise.

key points

• For patients with acute ischemic stroke and occlusion of a large vessel who present late after the onset of stroke but who have small infarct core and a large volume of tissue at risk late thrombectomy appears beneficial.
• The results of the DAWN and the DEFUSE 3 trials do not support a general extension of the time window for thrombectomy.
• Selection of patients who may benefit from late thrombectomy can be done using magnetic resonance imaging or perfusion computed tomography to identify the presence of viable tissue at risk; the role of the evaluation of collateral circulation which may be more easily available in some centers requires further evaluation.

Nogueira RG, Jadhav AP , Haussen DC et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018 ;378(1):11-21.

Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, Sarraj A, Kasner SE, Ansari SA, Yeatts SD, Hamilton S, Mlynash M, Heit JJ, Zaharchuk G, Kim S, Carrozzella J, Palesch YY, Demchuk AM, Bammer R, Lavori PW, Broderick JP, Lansberg MG; DEFUSE 3 Investigators. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018 Jan 24. doi: 10.1056/NEJMoa1713973.

Updates In Neurology | Neurology 2018 | Abstracts Invited | Berlin Conference

New Classification of Tremor released by the International Parkinson and Movement Disorder Society

Abstracts Submission at  https://neurology.cmesociety.com/abstract-submission  

Differential diagnosis of tremor syndromes is challenging task for neurologists. The need of a new classification scheme arises from recent developments in the clinical definition of specific tremor syndromes such as dystonic tremor, as well from the recent advances in the surgical treatment. That is, a precise diagnostic definition is required. The Task Force on Tremor of the International Parkinson and Movement Disorder Society has recently released a new classification aimed to provide a helpful tool for the clinicians approaching patients with tremor . 

The new scheme is based on two main axes: 1) clinical features; 2) etiology. 

This novel classification encourages the clinicians to first describe the clinical features, including historical features, tremor characteristics (in terms of topography, activation conditions and frequency), associated signs and additional laboratory tests (electrophysiology, functional and structural imaging, serum and tissue biomarkers). 

Accordingly, axis I allows to distinguish isolated from combined tremor syndrome. Axis II defines three main categories for etiology (acquired, genetically defined or idiopathic, either familial or sporadic). With this scheme, a tremor syndrome may have multiple etiologies, and a certain etiology may lead to multiple syndromes. A major advance of the new classification is that Essential Tremor is recognized as a syndrome with multiple etiologies. The new classification scheme of tremors represents a step forward in the Movement Disorders field to accurately define tremor syndromes and allows recruiting homogenous patient populations for further research studies.

key points

1. The novel classification of tremor syndromes is based on two main axes.

2. Axis I allows to distinguish isolated from combined tremor syndrome.

3. Axis II is an aid to define etiology.

4. In new classification, Essential Tremor is recognized as a syndrome with multiple etiologies.

5. The new classification provides a useful tool for precise diagnostic definition of patients with tremor syndromes 

Courtesy 

Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, Raethjen J, Stamelou M, Testa CM, Deuschl G, and the Tremor Task Force of the International Parkinson and Movement Disorder Society.

Consensus Statement on the classification of tremors. From the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018 Jan;33(1):75-87. 

Abstract Submission | Alzheimer's Disease (AD) | Causes | Diagnosis | Treatment | Neurology 2018 | Pulsus Conference

Alzheimer's Disease (AD)

Is the most common cause of dementia. Because its frequency increases with age, the number of people it strikes is growing as the population ages. In addition to memory loss, the first signs of Alzheimer's often include language difficulties and trouble with routine activities, such as driving and shopping. Mood changes may also occur. As the disease progresses, long-term memory may also be affected, and behavioural changes such as aggression, agitation, delusions and verbal outbursts may occur. The ability to carry out daily tasks, such as dressing or bathing, may be compromised. In severe Alzheimer’s, the abilities to talk and walk may be lost.

Causes of Alzheimer's Disease

Alzheimer's is a neurodegenerative disease, which means neurons (brain cells) progressively degenerate, eventually losing function and dying. Cells in the hippocampus, a seahorse-shaped structure deep in the brain that plays a major role in the formation of memories, appear to be especially vulnerable. In brain-imaging studies of people with Alzheimer's, the hippocampus is consistently smaller than normal. Accumulation of beta amyloid in nerve cells, in between the nerve cells and in the small blood vessels, together with vascular changes and possibly inflammation, are features of AD. There may be an inherited predisposition, but no specific cause has been identified in AD. The symptoms start insidiously and progress steadily over 10-20 years.
The brain pathways that link the hippocampus to other brain regions are also damaged, especially for those that lead to the prefrontal cortex, the brain’s control centre for cognitive functions. Many scientists believe this damage may be responsible for the persistent short-term memory problems that appear in the early stages of the disease.

Common Symptoms of Alzheimer's Disease

Each person with Alzheimer's may experience different symptoms, and symptoms may change over the course of the disease. Some of the common ones are described below.

• Difficulty in recalling names, objects, places, times and dates
• Not recognising family and friends, or not recalling their names
• Forgetting one’s own phone number or address
• Difficulty finding your way to or from a familiar place
• Tendency to wander from home or office
• Day/night disorientation with difficulty sleeping
• Noticeable language and intellectual decline
• Poor judgement, inability to follow simple instructions or stay focused on a task
• Progressive sense of distrust
• Dulled emotions or interest in activities
• Depression
• Unusual agitation and irritability
• Hallucinations or delusions

(source: Alzheimer's Association)

Diagnosing Alzheimer's Disease

The earliest signs of Alzheimer's disease are usually first noticed by a friend or relative. If you or someone close to you is experiencing any of the symptoms listed in “Common Symptoms of Alzheimer's Disease”, it is important to see a doctor as early as possible to determine the cause. Memory loss could be the result of a number of things, many of which may be reversible.
Currently, the only definitive diagnosis for Alzheimer's disease is based on an examination of brain tissue during autopsy. To establish a clinical diagnosis, doctors focus on ruling out, by process of elimination, all other possible causes of symptoms to determine whether AD might be the cause.

The evaluations your doctor should perform include:

• Medical history – current medical or psychological conditions, including a thorough review of personal and family health history and medications being used
• Neurological examination - assesses one’s sense of time and place, ability to remember, understand and communicate, and complete simple calculations
• Physical examination - evaluation of nutritional status, blood pressure, and pulse rate

If these initial examinations don't reveal a clear problem, additional tests might include:

• Brain imaging scans, such as MRI or CT, to look for tell-tale brain changes
• Laboratory tests, including blood and urine tests to try to identify blood-based or hormonal irregularities
• More extensive neuropsychological evaluations, which might include tests of memory, reasoning, vision-motor co-ordination, and language function
• Psychiatric evaluations, to assess mood and other emotional factors.

A diagnosis of Alzheimer's Disease is usually said to be either:

Probable: All other disorders that may cause dementia have been ruled out; or
Possible: AD is suspected, but other causes cannot be ruled out

Treatment for Alzheimer's Disease

As science progresses toward a better understanding of what kills brain cells in Alzheimer's disease, the hope is that medicines or other therapies might be developed to delay, prevent or reverse the damage. Clinical trials are underway for drugs, as well as a vaccine, that seek to interrupt the build-up of amyloid in the brain. If they are found to be safe and effective, these would be the first treatments that address what many experts think is the underlying cause of cell death. Unfortunately, it could take years for these therapies to reach patients. In the meantime, the primary goals of therapy for AD are to improve the quality of life and day-to-day functioning.
Current treatments for Alzheimer's include three relatively new medications that increase brain levels of acetylcholine, a neurotransmitter involved in the learning and memory processes. These drugs - Aricept, Exelon and Reminyl - have been modestly successful in some patients for improving memory and attention skills, and they may also have a beneficial effect on behavioural symptoms such as aggression.
Treatments may also target behavioural symptoms associated with AD, such as agitation, delusions, hallucinations, depression, or sleep difficulties. Medications to control these problems might include anti-depressants (such as Prozac, Zoloft and others), or sleep aids (such as Zopiclone). Consistent medical and psychological therapy is important for the individual as well as for family members.


Know more at :- https://neurology.cmesociety.com/abstract-submission

Lets Discuss More at :-https://neurology.cmesociety.com/

Submit Your Papers at :- https://neurology.cmesociety.com/abstract-submission

Primary symptoms of Parkinson’s disease | Abstracts Invited

For Abstract Submission Click Here

Primary symptoms of Parkinson’s disease

The primary symptoms of Parkinson’s disease are all related to voluntary and involuntary motor function and usually start on one side of the body. Symptoms are mild at first and will progress over time. Some individuals are more affected than others are. Studies have shown that by the time that primary symptoms appear, individuals with Parkinson’s disease will have lost 60% to 80% or more of the dopamine-producing cells in the brain. Characteristic motor symptoms include the following:

• Tremors: Trembling in fingers, hands, arms, feet, legs, jaw, or head. Tremors most often occur while the individual is resting, but not while involved in a task. Tremors may worsen when an individual is excited, tired, or stressed.
• Rigidity: Stiffness of the limbs and trunk, which may increase during movement. Rigidity may produce muscle aches and pain. Loss of fine hand movements can lead to cramped handwriting (micrographia) and may make eating difficult.
• Bradykinesia: Slowness of voluntary movement. Over time, it may become difficult to initiate movement and to complete a movement. Bradykinesia together with stiffness can also affect the facial muscles and result in an expressionless, “mask-like” appearance.
• Postural instability: Impaired or lost reflexes can make it difficult to adjust posture to maintain balance. Postural instability may lead to falls.
• Parkinsonian gait: Individuals with more progressive Parkinson’s disease develop a distinctive shuffling walk with a stooped position and a diminished or absent arm swing. It may become difficult to start walking and to make turns. Individuals may freeze in mid-stride and appear to fall forward while walking.

Secondary symptoms of Parkinson’s disease

While the main symptoms of Parkinson’s disease are movement-related, progressive loss of muscle control and continued damage to the brain can lead to secondary symptoms. These vary in severity, and not every individual will experience all of them. Some of the secondary symptoms include:

• anxiety, insecurity, and stress
• confusion, memory loss, and dementia (more common in elderly individuals)
• constipation
• depression
• difficulty swallowing and excessive salivation
• diminished sense of smell
• increased sweating
• male erectile dysfunction
• skin problems
• slowed, quieter speech, and monotone voice
• urinary frequency/urgency

4th International Conference on Neurology and Healthcare

We the Pulsus Group gladly invites all the healthcare aspirants and neurology aspirants to the grand conference of neurology to be held in Berlin, Germany during September 17-18 ,2018.

The CME event is on its progress as we have a great team of OCM, Speakers, Students, Delegates, Collaborators and Media Partners.

Be a part of the team as simple as this.

Submit your Abstracts 

or mails us at neurolcare2018@gmail.com 

OCM Panel

Dr.Robert Buckingham

Dr.Gary W jay

Prof.Mihoko Tomida

Dr.Saber Chebel

Collaborators 

German Society for Immunology

Media partners 

Pink Medico Medgadget Tabeeby  crowd reviews

kind congress placid way Enliven Archive

CourseForDoctors

medical events guide

plus 91 Bio Equip

expo group wellness china

expo book

Bentham Science

Abstracts Received 

Mr. opeoluwa akinyemi

Mr. Ujitha Bandara

Dr. Dilshoda Akramova

Prof.Mihoko Tomida

Dr. Soheil Kazemi

Dr. Robert Buckingham

Mr.Mohammad Abdullah

Dr. Ahlam Mustafa

Ms. Muborakkhon Rozikova

Sponsor Opportunities | Neurology 2018

NEUROLOGY 2018 CONFERENCE

4th International Conference on Neurology and Health Care

Theme: Broader Outlook in the Field of Neurology and Health Care

Dates: September 17-18, 2018Venue: Berlin, Germany

Why with us?

In today’s economic climate your business decisions are as crucial as ever. 4th International Conference on Neurology and Health Care allows you to maximize your time and marketing dollars while receiving immediate feedback on your new products and services.

4th International Conference on Neurology and Health Care is organizing an outstanding Scientific Exhibition/Program and anticipates the world’s leading specialists involved in .

Neurology 2018 organizing committee anticipates over 300 participants to attend this premier event. Your organization will benefit with excellent exposure to the leaders in Healthcare.

Neurology 2018 is an exciting opportunity to showcase the new technology, the new products of your company, and/or the service your industry may offer to a broad international audience.

Lots of thoughts were put together planning to make this conference a premier event. Our worldwide Editorial Board Members of The Neurosurgery Journal and Journal of Neurology and Clinical Neuroscience and Journal of Clinical Psychiatry and Neuroscience have agreed to promote and support the event.

Exhibiting at 4th International Conference on Neurology and Health Care will attain you with an exceptional format in showcasing your products and services. Pulsus Conferences and Exhibitions provide you one location to reach your top customers.

Premium Sponsorship Packages

Elite Sponsor

• An opportunity to sponsor 10 Poster Presentation Awards.
• Three corporate sponsored workshop slots (audio visual included).
• Two complimentary exhibit booths with priority to purchase exhibition space and choose booth location (Booth size-3X3 sqm).
• Four complimentary registrations.
• Logo recognition on congress website front page with link, logo recognition on congress sponsorship page and logo recognition on corresponding PULSUS Journal home page.
• One A4 color advertisement in the congress program or book of abstracts (excluding cover pages).
• Three inserts provided by the sponsor in the congress delegate bags.
• One post congress e-mail message to consented congress registrants up to 60 days after the congress (content to be provided by the sponsor, approved and distributed by corresponding Journal).
• An exclusive online Promotion on all our Social Networking Sites.
• 20% Waiver on Sponsorship for any of our next year conferences.

Gold Sponsor

• An opportunity to sponsor 5 Poster Presentation Awards.
• Two corporate sponsored workshop slot (must honor deadlines, catering and audio visual included).
• One complimentary exhibit booth with priority to purchase exhibition space and choose booth location (Booth size-3X3 sqm).
• Three complimentary congress registrations.
• Logo recognition on congress website front page with link and logo recognition on congress sponsorship page.
• One A4 color advertisement in the congress program or book of abstracts (excluding cover pages).
• Two inserts provided by the sponsor in the congress delegate bags.
• An exclusive online Promotion on all our Social Networking Sites.
• 15% Waiver on Sponsorship for any of our next year conferences.

Silver Sponsor

• An opportunity to sponsor 3 Poster Presentation Awards.
• Two complimentary congress registrations.
• One corporate sponsored workshop slot (must honor deadlines, catering and audio visual included).
• One complimentary exhibit booth with priority to purchase exhibition space and choose booth location (Booth size-3X3 sqm).
• Logo recognition on congress website sponsorship page.
• One A4 color advertisement in the congress program or book of abstracts (excluding cover pages).
• One insert provided by the sponsor in the congress delegate bags.
• Priority to purchase additional sponsorship items.
• An exclusive online Promotion on all our Social Networking Sites.
• 10% Waiver on Sponsorship for any of our next year conferences.

Exhibition

• An opportunity to sponsor one poster presentation award.
• One complimentary congress registration.
• Set up of one tailor-made exhibit booth (Booth Size 3x3 sqm).
• Logo recognition on congress website sponsorship page.
• A4 Color Advertisement in Congress Program or Book of Abstract.
• Inclusion of your company’s leaflet/insert in the congress delegate bags.
• An exclusive online promotion on all our social Networking Sites.
• 5% Waiver on Sponsorship for any of our next year conferences.
• Recognition to your products and services in the world market through our website.
• Develop new client relationships and strengthen the existing ones (B2B Meeting).
• Shape and raise your corporate image through logo branding.
• Brand briefing at the opening and closing ceremonies.
• Press Release on behalf of your company.
• Brand announcement with 50000 Brochures across the Globe.
• Sharing Conference Posters (10000) with Industries and Universities located across the globe.

Additional Sponsorship Packages

Lunch / Cocktail Sponsor

Coffee Break Sponsor

Conference Delegate Bag Sponsor

Bag Insert Sponsor

Lanyard (also known as neck cords)

Advertisements

Outside Back Cover (color)

Inside Front Cover (color)

Inside Back Cover (color)

Per Page

Neurology 2018

Deadly brain cancer stopped with new compound

4th International Conference on Neurology and Healthcare

Deadly brain cancer stopped with a new compound

Abstract submission @ https://neurology.cmesociety.com/abstract-submission 

Glioblastoma, one of the deadliest forms of brain cancer, may have found its nemesis. New research shows that a tumour, which is notoriously difficult to treat, can be halted by an experimental compound.

New research shows that an experimental compound can stop aggressive brain tumours from growing.

Glioblastoma is a particularly aggressive form of a brain tumour, with a median survival rate of 10–12 months.
Part of the reason why glioblastomas are so deadly is that they arise from a type of brain cell called astrocytes.
These cells are shaped like a star, so when the tumours form they develop tentacles, which makes them difficult to remove surgically.

Additionally, the tumours advance rapidly. This is because astrocytes provide support to neurons and control the amount of blood that reaches them; so, when tumours form, they have access to a large number of blood vessels, helping cancerous cells to grow and spread very quickly.
Another reason that glioblastomas are so difficult to treat is their high rate of recurrence.

 This is partly due to a subpopulation of cells contained in a tumour called glioma stem cells (GSC) — a type of self-regenerating cancer stem cell that controls the growth of tumours.

Subhas Mukherjee, Ph.D., a research assistant professor of pathology at the Northwestern University Feinberg School of Medicine in Chicago, IL, and his colleagues have been studying the behaviour of these cells for a few years. Building on this previous research, Mukherjee and team have now found that these cells contain high levels of an enzyme called CDK5.

Blocking this enzyme, the researchers show in their new study, stops glioblastomas from growing and inhibits the self-regenerating capabilities of GSCs.

The findings were published in the journal Cell Reports.

6 Ways to Strengthen Your Nervous System

4th International Conference on Neurology and Healthcare

The nervous system, one of the most complex and important parts of our body, is responsible for responding to external (through our senses) and internal stimuli and for responding to them with different corporal actions.

Visit For More details  https://neurology.cmesociety.com/

Since the nervous system is responsible for controlling the larger part of our vital functions (breathing, heartbeats, hunger, thirst, posture, etc.) as well as for our emotions (happiness, sadness, etc.), it is important to strengthen it naturally to ensure a good quality of life.

Three Beneficial Foods

There are some specific foods that positively regulate our nervous system:

• Baker’s yeast: Thanks to its B vitamins, it is also a good reinforcer of the central nervous system, and therefore it can help improve cases of depression, anxiety, stress, apathy, or lack of appetite.  We can eat it in powder form, mixed with juice or yoghurt, or in tablet form, if we don’t like the slightly bitter flavour.  Some brands sell it debittered to soften its flavour.  If we take it with food, it will improve nutrition assimilation.
• Oatmeal:  This delicious cereal acts as a nervous system stabilizer.  It calms irritable states and mild anxiety, relieves insomnia, including in small children, and increases mental performance.  It is strangely a food that both relaxes and gives energy.  We can eat it cooked, sweet or salty, boiled with milk with a little cinnamon, or with creamed vegetables.  We can also drink oatmeal “milk”.
• Bee Pollen: Pollen is a superfood.  It equalizes the blood pH and nervous system function thanks to its B vitamins.  We will take a tablespoon of ground pollen every morning, mixed with a bit of water, juice, or yoghurt.

Magnesium

Alterations in the nervous system, such as insomnia, anxiety, hyperactivity, worry, or panic attacks can be symptoms of a lack of magnesium in our bodies.
It is recommended, in these cases, to daily consume foods rich in magnesium, such as:

• Cocoa: Dark chocolate has almost 500 mg of magnesium per 3.5 ounces.
• Green leafy vegetables: Swiss chard, lettuce, spinach.
• Fruit: Banana, apricot, avocado, melon, plum.
• Nuts: Almonds, cashews, hazelnuts, walnuts.
• Legumes: Peas, lentils.
• Cereal: Brown rice, millet, oats.
• Seeds
• Potatoes
• Pumpkin
  

  

  Chocolate is a great source of magnesium. 3.5 oz of dark chocolate contains 146 mg of magnesium.

We can also opt for a magnesium supplement.  In this case, we will take three grams every day, orally, three times a day so the body can absorb it properly, which is one gram per meal.

Medicinal Plants

The following medicinal plants act as relaxants and boosters of the nervous system.  We can take them as infusions or extracts, or use as air fresheners in our home, and on our skin as essential oils:

• Lemon balm
• Ginkgo biloba
• Hypericum
• Basil
• Lavender
• Passionflower

Sunlight

Sunlight is an excellent regulator of the nervous system and it also provides us with vitamin D.  To benefit from it, we can sunbathe for 10 to 15 minutes per day, preferably in the morning or late afternoon.

Walking Barefoot in a Natural Environment

Walking barefoot on the moist earth, dewy grass, beach sand, in a river, in the sea, etc., during at least half an hour a day is the most economical and healthy way to balance our nervous system.  In addition, it helps us to eliminate electromagnetic radiation that we absorb in our body from continuous contact with electronic devices.  We recommend that you test it out, as the results can be noticed from the first day.

Water Therapy

Water at different temperatures helps us to balance our nervous system.  We can do various therapies:

• Cool, wet rubs with a very thin towel, not dried, following the following pattern: hand-shoulder, foot-groin, torso.  We will do this quickly at first, and then we will dress warmly to enter into the heat.
• Alternating arm baths.  We will begin by putting our arms in hot water, briefly, one at a time.  The final one has to be cold.  They will last about 30 seconds each.
• In general, always ending a bath with a few seconds of a cold shower is very beneficial.  We will avoid the head region.
• Finally, magnesium sulfate baths (about 100 grams) are very relaxing and revitalizing.

For More Details  https://neurologyconference2018194170395.wordpress.com

Neurology 2018

                      4th International Conference on Neurology and Healthcare

Let's move together to witness the platform of future healthcare in Berlin, Germany

Pulsus group hosts the 4th International Conference on Neurology and Healthcare (Neurology 2018) which is scheduled on September 17-18,2018 at Berlin, Germany. The event will be a great platform for the researchers, postdoctoral fellows and other healthcare professionals to enhance their academic path in a well suitable form. The event will discuss the most recent advancements in the field of #neurology and #healthcare thereby creating a gate towards modern healthcare.

Join us on Facebook @ https://www.facebook.com/events/1570389336377828/ 
Twitter @Neurocare2018
Instagram @Neurology2018
G+ @ https://plus.google.com/u/0/events/c0vf1p178stqid4aflo7slo4sss

STUDENT AMBASSADORS

INVITATION: -STUDENT AMBASSADORS

 4th International Conference on Neurology and Healthcare is scheduled for September 17-18,2018 at Berlin, Germany.

We would also like to have  Student Ambassadors from your University / Association as this conference will provide them a great opportunity to interact with renowned speakers, doctors , researchers which could fulfil their academic interest.

Interested students can contact us directly in the mail: neurocare2018@gmail.com  | neurocare2018@rediffmail.com 


You could visit:  https://neurology.cmesociety.com 

CALL FOR SPEAKERS

4th International Conference on Neurology and Healthcare

Neurology 2018  serves as an emerging platform to discuss about the recent advancements in neurology and healthcare which includes neuro robotics, deep brain simulation , neuro surgery , precision medicine for neural disorders and more…..

Neurology 2018 will be a grand event which is focused on the theme “Broader Outlook in the Field of Neurology and Healthcare” and ensures better advancements in healthcare for the future.

For a better healthcare in the future we would like to engage in a Conference which will track the valuable decisions from the world, hence being a part of it , I  would like to invite you to the “4^th International Conference on Neurology and Healthcare” scheduled during September 17-18, 2018 at Berlin, Germany, which will track the evolution in Neurology and Healthcare. 

The following main themes of the conference have been discussed during presentations of the two-day event, which will outsource the valuable points/decisions /research works for the better health care.

·         Research in Neurology and Neurosurgery

·         Advancements in Neurosurgery and Neuromedicine

·         Deep Brain Simulation

·         Education in Neurocare

·         Patient Safety and Neuro Monitoring

·         Neuro-Rehabilitation 

·         Innovation, Academic Leadership and Evaluation Research

·         Neuro Robotic Assistance

You could visit:  https://neurology.cmesociety.com . 

Let’s join together for the Conference. 

Contact us 

Chris Isaac 

neurocare2018@gmail.com | neurocare2018@rediffmail.com